The Life Sciences Report
Notable Quotes
"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More >
"ATHX is an exciting story and definitely a company to watch." (6/6/13) Athersys Inc. - The Life Sciences Report Interview with Christian Glennie More >
"NEO has been able to continue to grow the topline nicely and maintain margins of more than 45%." (5/30/13) NeoGenomics Laboratories - The Life Science Report with Kevin DeGeeter More >
"OPK's 4Kscore is approved in Europe and should be approved in the U.S. sometime in 2013." (5/30/13) OPKO Health Inc. - The Life Science Report with Kevin DeGeeter More >
"CTH is very early in the game with a very good and relatively derisked idea." (5/30/13) Cynapsus Therapeutics Inc. - The Life Science Report with Ori Hershkovitz More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk High: | ||
Navidea Biopharmaceuticals Inc.TICKER: NAVB:NYSE
|